FDA Adds Boxed Warning to Canagliflozin Due To Increased Leg and Foot Amputation Risk

http://type2diabetestreatment.net/diabetes-type-2/fda-adds-boxed-warning-to-canagliflozin-due-to-increased-leg-and-foot-amputation-risk/
Lauren Biscaldi, Assistant Editor May 16, 2017 FDA Adds Boxed Warning to Canagliflozin Due To Increased Leg and Foot Amputation Risk Share this content:

• facebook
• twitter
• linkedin
• google

Canagliflozin use is associated with increased risk of toe, foot, and leg amputations.

Data from 2 large clinical trials have confirmed that treatment of type 2 diabetes with canagliflozin (Invokana®, Invokamet®, and Invokamet XR®; Janssen Pharmaceuticals, Inc.) may lead to an increased risk of leg and foot amputations, according to a US Food and Drug Administration (FDA) Drug Safety Communication.1

The announcement — an update to a similar communication issued in May 20162 — cites data from CANVAS (Canagliflozin Cardiovascular Assessment Study; ClinicalTrials.gov identifier NCT01032629) and CANVAS-R (A Study of the Effects of Canagliflozin [JNJ-28431754] on Renal Endpoints in Adult Participants With Type 2 Diabetes Mellitus; ClinicalTrials.gov identifier NCT01989754), which found that leg and foot amputations occurred “about twice as often in patients treated with canagliflozin compared to patients treated with placebo,” according to the FDA announcement.

Continue Reading Below

Over one year, amputation risk for patients in CANVAS and CANVAS-R was equivalent to 5.9 and 7.5 out of every 1000 patients treated with canagliflozin, respectively, compared with 2.8 and 4.2 out of every 1000 patients treated with placebo. The most common amputations resulting from canagliflozin therapy were of the toe and middle of the foot, although above-knee and below-knee leg amputations were also reported.

As a result, the FDA will require canagliflozin drug labels to include prominent boxed warnings describing the risk to patients.

Health care professionals and patients are advised to report adverse effects and serious issues resulting from canagliflozin use to the FDA MedWatch program

Related Articles

• Renal Injury Warnings for Canagliflozin, Dapagliflozin Strengthened by FDA
• FDA: Interim Trial Results Link Diabetes Drug to Potential Increased Risk for Amputations
• Incidence of Diabetic Ketoacidosis Low With Canagliflozin in Type 2 Diabetes

Reference

1. FDA Drug Safety Communication: FDA confirms increased risk of leg and foot amputations with the diabetes medicine canagliflozin (Invokana, Invokamet, Invokamet XR). Silver Spring, MD: US Food and Drug Administration. https://www.fda.gov/Drugs/DrugSafety/ucm557507.htm. Published May 16, 2017. Accessed May 16, 2017.
2. FDA Drug Safety Communication: Interim clinical trial results find increased risk of leg and foot amputations, mostly affecting the toes, with the diabetes medicine canagliflozin (Invokana, Invokamet); FDA to investigate. Silver Spring, MD: US Food and Drug Administration. https://www.fda.gov/Drugs/DrugSafety/ucm500965.htm. Published May 18, 2016. Accessed May 16, 2017.

Related Topics

• Diabetes
• Diabetes Complications
• Type 2 Diabetes

Endocrinology Advisor Articles

• Does PCOS Increase Depression and Anxiety Symptoms?
• Post-PCI HbA1c Levels Predict Cardiac, Cerebrovascular Events in Diabetes
• FDA Approves Abaloparatide for Fragility Fracture in Postmenopausal Women With Osteoporosis
• Diabetes Medication May Be Protective against Atrial Fibrillation
• Case Study: How Can Dietary Supplement Use Lead to Thyroid Disease?

• Liraglutide Plus Metformin Leads to Remission in New-Onset Type 2 Diabetes
• Early Insulin Therapy Improves Type 2 Diabetes Care
• Comorbid Congestive Heart Failure Linked to Worse Outcomes When Receiving Parenteral Nutrition
• Migraine Management in Female Reproduction
• Testosterone Replacement Therapy May Protect Against Stroke, Heart Attack in Hypogonadism

• FDA Adds Boxed Warning to Canagliflozin Due To Increased Leg and Foot Amputation Risk
• Brain Function Abnormalities With Overweight/Obesity in Type 2 Diabetes
• Factors Influencing Physician Burnout
• Behavioral Programs Increase Weight Loss in Adults With Obesity
• The Ugly Truth: Persistent Sexism in Medicine

Sign Up for Free e-Newsletters

Type 2 Diabetes Treating
Renal Diabetic Diet
Advanced Diabetic Solutions
Original Article
#Diabetes_Type_2
#obesity_help